![](\"https:\/\/mms.businesswire.com\/media\/20260702409370\/en\/2843772\/5\/Arima-Genomics-logo.jpg\"){kind=logo}
<\/a><\/a>\nUnder the terms of the agreement, Active Motif will receive the distribution rights to Arima\u2019s full suite of 3D genomics research kits and services for non-formalin fixed paraffin embedded (FFPE) sample types, including cell lines, blood, and fresh-frozen tissues. Applications of these tools include epigenetics and gene regulation, human health and disease research, as well as reference-quality genome assembly and haplotype phasing to advance functional and evolutionary genomics.<\/p>
\nThe distribution partnership is part of Arima\u2019s broader strategy to enhance its strategic focus on its core clinical diagnostic platform, which leverages proprietary Hi-C sequencing technology to capture the structural organization of cancer genomes from routine FFPE samples. This technology provides the foundation for the Company\u2019s current clinical tests, Aventa FusionPlus for solid tumors and Aventa Lymphoma, both of which detect actionable fusions and rearrangements that conventional workflows may miss or incompletely characterize.<\/p>
\n\u201cWe believe the future of cancer diagnostics lies in understanding more of what the genome has to reveal \u2014 bringing together DNA sequence and structure to expose the true drivers of disease,\u201d said Tom Willis, Ph.D., CEO of Arima Genomics. \u201cThis agreement allows Arima to focus our resources on advancing that vision through our Aventa clinical diagnostics platform, while ensuring that researchers continue to access these tools through Active Motif\u2019s established commercial infrastructure, complementary product portfolio and deep relationships across the life sciences research community.\u201d<\/p>
\n\u201cArima has built a differentiated technology platform that is changing how clinically meaningful genomic alterations are detected and understood in cancer,\u201d said Malek Faham, M.D., Ph.D., Chief Scientist at Illumina Ventures. <\/b>\u201cThis agreement sharpens the Company\u2019s focus on the clinical opportunity, where it is well positioned to address important limitations of conventional testing and deliver insights that can inform patient care.\u201d<\/p>
\nAbout Arima Genomics<\/b><\/p>
\nArima Genomics is a cancer diagnostics company redefining cancer testing by bringing DNA sequence and structure together. Built on leadership in 3D genome science and Hi-C sequencing technology, Arima develops clinical tests that reveal cancer-driving alterations conventional approaches can miss or incompletely characterize. Through its Aventa clinical testing brand, Arima offers testing for solid tumors and lymphoma from its CLIA-certified laboratory in Orlando, Florida. Learn more at www.arimagenomics.com<\/a> and aventatest.com<\/a>, and follow us on LinkedIn<\/a>.<\/p> \nAbout Active Motif<\/b><\/p> \nActive Motif is a leading provider of epigenetics, genomics, and multiomics solutions that enable researchers to investigate gene regulation, chromatin biology, and disease mechanisms. Through innovative products, services, and scientific expertise, Active Motif supports researchers worldwide in advancing discoveries that improve human health.<\/p>